Showing results (301-310 of 600) with videos related to

Sort By:
Pageof 60
Neotropical Entomology|July 4, 2007
[Susceptibility of six Arabic coffee cultivars to fruit flies (Diptera: Tephritoidea) under shaded and unshaded organic management in Valença, State of Rio de Janeiro, Brazil]Elen L Aguiar-Menezes, Silvana A S Souza, Carlos M A Santos, et al.
European Journal of Haematology|January 26, 1999
Antibodies reactive with neutrophils following allogeneic haematopoietic stem cell transplantationP L Tazzari, D Rondelli, F Re, et al.
ESMO Open|September 15, 2022
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumorsC Le Tourneau, H Becker, R Claus, et al.
Leukemia|February 19, 2011
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemiaC Evangelisti, F Ricci, P Tazzari, et al.
Leukemia|October 12, 2007
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cellsV Papa, P L Tazzari, F Chiarini, et al.
Clinical and Experimental Immunology|January 24, 2004
Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studiesG L Palmisano, P L Tazzari, E Cozzi, et al.
Eye (London, England)|September 16, 2017
Assessing individual risk for AMD with genetic counseling, family history, and genetic testingR Cascella, C Strafella, G Longo, et al.
Discover Oncology|February 24, 2022
Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinomaM Mancini, A Cappello, R Pecorari, et al.
International Journal of Immunopathology and Pharmacology|October 14, 2009
Angiogenic potential of human dental pulp stromal (stem) cellsC Marchionni, L Bonsi, F Alviano, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
Pageof 60